Zhong-Zhe Lin

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

Richard D. Kim, Debashis Sarker, Tim Meyer et al. · Cancer Discovery · 2019 · 239 citations · Full text

Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma

Yen‐Shen Lu, Yoko Kashida, Samuel K. Kulp et al. · Hepatology · 2007 · 90 citations · Full text

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

Shukui Qin, Stephen L. Chan, Wattana Sukeepaisarnjaroen et al. · Therapeutic Advances in Medical Oncology · 2019 · 58 citations · Full text

The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma

Zhong-Zhe Lin, Hey-Chi Hsu, Chih‐Hung Hsu et al. · Journal of Hepatology · 2008 · 45 citations

Human Hepatocellular Carcinoma, Medicine, Pre-clinical Studies +7

Efficacy, Safety, and Potential Biomarkers of Thalidomide plus Metronomic Chemotherapy for Advanced Hepatocellular Carcinoma

Yu‐Yun Shao, Zhong-Zhe Lin, Chiun Hsu et al. · Oncology · 2012 · 29 citations